FDA Adverse Event Malfunction Summary report: N

INFUSOR

MDR report key: 2091589 · Received May 17, 2011

Report

Report Number
6000001-2011-04128
Event Type
Malfunction
Date Received
May 17, 2011
Date of Event
April 1, 2011
Report Date
April 28, 2011
Manufacturer
BAXTER HEALTHCARE - IRVINE
Product Code
MEB
PMA / PMN Number
K982102
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THE DEVICE HAS BEEN RECEIVED BY BAXTER FOR EVALUATION; HOWEVER, THE EVALUATION HAS NOT YET BEEN COMPLETED. A FOLLOW-UP REPORT WILL BE SUBMITTED UPON COMPLETION OF THE EVALUATION AND/OR SHOULD ANY ADDITIONAL INFORMATION BECOME AVAILABLE.

Additional Manufacturer Narrative · 1

(B)(4). EVALUATION SUMMARY: BAXTER RECEIVED ONE SAMPLE FOR EVALUATION. VISUAL EXAMINATION CONFIRMED THE REPORTED CONDITION OF A RUPTURED RESERVOIR. APPROXIMATELY 60 ML OF SOLUTION WAS ALSO NOTED IN THE HOUSING DUE TO THE RUPTURE. THE ROOT CAUSE WAS DETERMINED TO BE A MANUFACTURING DEFECT. NO OTHER OBSERVATIONS WERE NOTED ON THE UNIT. NO REPAIR WAS DONE, AS THIS IS A SINGLE-USE DEVICE WHICH WILL BE DISCARDED. PER REVIEW OF THE BATCH RECORDS, NO NONCONFORMANCE REPORT WAS DOCUMENTED FOR THIS LOT. ALL RELEASE CRITERIA WERE MET FOR THE BUILD OF THE LOT. BAXTER HAS CONDUCTED A TREND REVIEW AND FOUND THAT SIMILAR REPORTS HAVE BEEN RECEIVED FOR THE REPORTED PROBLEM. THE ROOT CAUSE INVESTIGATION IS IN PROGRESS THROUGH (B)(4). (B)(4).

Description of Event or Problem · 1

BAXTER (B)(4) RECEIVED A REPORT THAT ONE (1) HALF-DAY INFUSOR DEVICE REPORTEDLY RUPTURED WHILE BEING FILLED WITH DESFERRIOXAMINE. THIS OCCURRED PRIOR TO PATIENT USE, THERE IS NO PATIENT INVOLVEMENT, INJURY, OR MEDICAL INTERVENTION. NO ADDITIONAL INFORMATION IS AVAILABLE. THIS REFERENCES REPORT 2 OF 2 FOR THE FACILITY, AS THE FACILITY REPORTED 2 DEVICES.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 INFUSOR PUMP, INFUSION, ELASTOMERIC MEB BAXTER HEALTHCARE - IRVINE 11B068

Patients

Seq Age Sex Outcome Treatment
1 DESFERRIOXAMINE